此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Turkish Validity and Reliability of the Parkinson's Disease Neuropsychometric Dementia Assessment Questionnaire in Individuals With Parkinson's Disease

2026年9月11日 更新者:Nuray Alaca、Acibadem University
The aim of this study is to examine the validity and reliability of the Turkish version of the Parkinson's Neuropsychometric Dementia Assessment (PANDA) in individuals with Parkinson's disease. This cross-sectional methodological study will evaluate the psychometric properties of the Turkish PANDA, including internal consistency, test-retest reliability, and construct validity, in order to provide a valid and reliable instrument for the assessment of cognitive impairment and dementia-related cognitive changes in Turkish-speaking individuals with Parkinson's disease.

研究概览

研究类型

观察性的

注册 (估计的)

100

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

The study population will consist of individuals with clinically diagnosed Parkinson's disease (Hoehn and Yahr stage 1-3), aged between 40 and 85 years, with adequate cognitive function (MMSE ≥ 24). Participants will be recruited from patients attending the Movement Disorders Outpatient Clinic of the Neurology Department. The study population represents ambulatory individuals with mild to moderate disease severity suitable for comprehensive biopsychosocial assessment.

描述

**Inclusion Criteria:**

  • Clinical diagnosis of Parkinson's disease
  • Hoehn and Yahr stage 1-3
  • Age between 40 and 85 years
  • Mini-Mental State Examination score ≥ 24
  • Sufficient cognitive and communication ability to complete the assessments
  • Attendance at the Movement Disorders Outpatient Clinic of the Neurology Department
  • Willingness to participate in the study and provide written informed consent

**Exclusion Criteria:**

  • Presence of a major psychiatric disorder, such as major depressive disorder or a psychotic disorder
  • Diagnosis of advanced dementia
  • Presence of an uncontrolled systemic chronic disease, such as uncontrolled diabetes mellitus or hypertension
  • Presence of a severe cardiovascular or respiratory condition
  • Presence of an additional orthopedic or neurological condition that may affect assessment performance
  • Severe visual or hearing impairment that may interfere with the assessments
  • Inability to cooperate adequately during the assessments

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
帕金森病
Participants will complete the Turkish version of the Parkinson Neuropsychometric Dementia Assessment (PANDA) as part of the psychometric evaluation process. The PANDA will be administered according to standardized instructions to assess cognitive performance in individuals with Parkinson's disease. To evaluate test-retest reliability, the Turkish PANDA will be re-administered to a subgroup of participants after a predefined interval under similar conditions. No therapeutic intervention will be provided as part of this methodological validation study.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Parkinson Neuropsychometric Dementia Assessment (PANDA) Total Score
大体时间:[Time Frame: Baseline (at the time of PANDA administration)]

Cognitive performance will be assessed using the Turkish version of the Parkinson's Neuropsychometric Dementia Assessment (PANDA) in individuals with Parkinson's disease. The PANDA is a brief cognitive screening instrument specifically developed for Parkinson's disease and includes tasks assessing learning and memory, verbal fluency, visuospatial processing, working memory, and delayed recall.

The PANDA total score ranges from 0 to 30, with higher scores indicating better cognitive performance. The psychometric properties of the Turkish version, including internal consistency, test-retest reliability, and construct validity, will be evaluated.

[Time Frame: Baseline (at the time of PANDA administration)]

次要结果测量

结果测量
措施说明
大体时间
Montreal Cognitive Assessment (MoCA) Total Score
大体时间:[Time Frame: Baseline (at the time of cognitive assessment)]

Global cognitive performance will be assessed using the Montreal Cognitive Assessment (MoCA), a widely used cognitive screening tool that evaluates multiple cognitive domains, including attention, executive functions, memory, language, visuospatial abilities, abstraction, calculation, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance.

MoCA scores will be used to evaluate the convergent construct validity of the Turkish version of the Parkinson Neuropsychometric Dementia Assessment (PANDA).

[Time Frame: Baseline (at the time of cognitive assessment)]
Mini-Mental State Examination (MMSE) Total Score
大体时间:[Time Frame: Baseline (at the time of cognitive assessment)]

General cognitive status will also be assessed using the Mini-Mental State Examination (MMSE), which evaluates orientation, registration, attention and calculation, recall, language, and visuospatial abilities. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance.

MMSE scores will be examined in relation to PANDA scores to further assess the convergent construct validity of the Turkish version of the PANDA.

[Time Frame: Baseline (at the time of cognitive assessment)]

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2026年11月1日

研究完成 (估计的)

2027年7月1日

研究注册日期

首次提交

2026年9月7日

首先提交符合 QC 标准的

2026年9月7日

首次发布 (实际的)

2026年9月11日

研究记录更新

最后更新发布 (实际的)

2026年9月14日

上次提交的符合 QC 标准的更新

2026年9月11日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅